Physician profile
Robert Shaw
NPI 1285699827
$801.22
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $309 · 2021: $50.83.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $233.34 | 2020 | |
| Sanofi-Aventis U.S. LLC | $121.38 | 2019 | |
| Glaxosmithkline, LLC. | $66.05 | 2019-2020 | |
| Medtronic USA, INC. | $62.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $56.81 | 2019 | |
| Abbvie INC. | $50.83 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.15 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $37.21 | 2019 | |
| Amgen INC. | $24.11 | 2019-2020 | |
| Shire North American Group INC | $15.69 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.69 | 2019 | |
| Sanofi Pasteur INC. | $12.81 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.11 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.94 | 2019 | |
| Novo Nordisk INC | $11.68 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Flowonix Medical Incorporated | $11.61 | 2019 | |
| Allergan, INC. | $11.25 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.